Gonadotropin releasing hormone agonist treatment before hysteroscopic endometrial resection

P. Vercellini, L. Trespidi, T. Bramante, S. Panazza, F. Mauro, P. G. Crosignani

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES: To evaluate the effects of treatment with the gonadotropin releasing hormone (GnRH) agonist goserelin before endometrial resection on absorption of distension medium fluid and technical feasibility of the surgical procedure. METHODS: Fifty-five patients reporting menorrhagia underwent endometrial resection after 2 months of goserelin depot therapy (33 cases) or during the proliferative phase of the cycle (22 controls). RESULTS: In the cases, the mean distension medium deficit ± S.D. was 511 ± 196 ml versus 647 ± 245 ml in controls (P = 0.03), and the operating times were, respectively, 14 ± 4 versus 18 ± 5 min (P = 0.002). The intrauterine operating conditions were considered excellent or good in 64% of the cases versus 27% of the controls (χ2 = 5.60, P = 0.02). CONCLUSIONS: GnRH agonists induce endometrial thinning, so that when administered before intrauterine interventions, mucus cellular debris and bleeding should be reduced during surgery and hysteroscopic visibility increased; the operating time may thus be shorter and fluid absorption decreased. However, more data are needed before considering GnRH agonists a proven effective means of facilitating endometrial resection.

Original languageEnglish
Pages (from-to)235-239
Number of pages5
JournalInternational Journal of Gynecology and Obstetrics
Volume45
Issue number3
DOIs
Publication statusPublished - 1994

Keywords

  • Gonadotropin releasing hormone agonists
  • Hysteroscopy
  • Menorrhagia
  • Uterine surgery

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Gonadotropin releasing hormone agonist treatment before hysteroscopic endometrial resection'. Together they form a unique fingerprint.

Cite this